Overview

Recent discoveries in genetics and genomics hold great promise for the development of target-defined prevention- and chemotherapeutic-strategies for breast and ovarian cancer.  However, a coordinated, multi-disciplinary research effort is required to translate these new research discoveries into the next generation of therapeutic strategies.  To meet this challenge the Breast and Ovarian Cancer Program aims to 1) define early events in breast and ovarian carcinogenesis, 2) translate these advances into targeted therapeutic approaches for the prevention and treatment of breast and ovarian cancer, and 3) test these new therapies in investigator-initiated and multi-institutional clinical trials. The Program includes 29 full and 10 associate members from twelve basic and clinical departments within Duke University. Since its inception, the Program has successfully fostered scientific interactions between members of the Duke Comprehensive Cancer Center (DCCC) who have basic, translational, and clinical research interests in breast and ovarian cancer. Within the domain of the Program we developed five subprograms that draw from our translational research strength and ability to translate basic science discoveries to impact the early detection and treatment of breast and ovarian cancer: 1) Early detection strategies for breast and ovarian cancer;  2) Methylation imprinting and epigenetic dysregulation;  3) Basic breast and ovarian cancer biology and novel therapeutic targeting; 4) Genomics; and 5) Disparities for African American women. The diversity of interest and experimental approaches used by the members of the Breast and Ovarian Program represents an effective environment for fostering cross-fertilization of ideas aimed at understanding breast and ovarian cancer. In addition, the Program supports developmental projects, new faculty awards, and tissue procurement and banking. From 2004-2008, program members published 737 papers in peer-reviewed journals that bear directly on breast and/or ovarian cancer (increased 498).  Program members are highly collaborative. Of these publications, 46% are the result of inter-programmatic collaborations and 51% due to intra-program collaborations (increased from 6% and 10% respectively in 2003).

High-Impact Journal Publications

Below are recent publications in high-impact journals from Cancer Center members in this program. To see journal articles for a particular member, click on the researcher's name in the Membership section.

---

Lu J,Guo H,Treekitkarnmongkol W,Li P,Zhang J,Shi B,Ling C,Zhou X,Chen T,Chiao PJ,Feng X,Seewaldt VL,Muller WJ,Sahin A,Hung MC,Yu D. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition., , (195-207) - Cancer cell Abstract [More ...]

Ellis MJ,Gao F,Dehdashti F,Jeffe DB,Marcom PK,Carey LA,Dickler MN,Silverman P,Fleming GF,Kommareddy A,Jamalabadi-Majidi S,Crowder R,Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study., , (774-80) - JAMA : the journal of the American Medical Association Abstract [More ...]

Joseph JD,Wittmann BM,Dwyer MA,Cui H,Dye DA,McDonnell DP,Norris JD. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists., , (12178-83) - Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Olson JA Jr,McCall LM,Beitsch P,Whitworth PW,Reintgen DS,Blumencranz PW,Leitch AM,Saha S,Hunt KK,Giuliano AE. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011., , (3530-5) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Anders CK,Hsu DS,Broadwater G,Acharya CR,Foekens JA,Zhang Y,Wang Y,Marcom PK,Marks JR,Febbo PG,Nevins JR,Potti A,Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression., , (3324-30) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Marks LB,Zeng J,Prosnitz LR. One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate., , (2075-7) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology No abstract available [More ...]

Seidman AD,Berry D,Cirrincione C,Harris L,Muss H,Marcom PK,Gipson G,Burstein H,Lake D,Shapiro CL,Ungaro P,Norton L,Winer E,Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840., , (1642-9) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Jirtle RL. Randy L. Jirtle, PhD: epigenetics a window on gene dysregulation, disease. Interview by Bridget M. Kuehn., , (1249-50) - JAMA : the journal of the American Medical Association No abstract available [More ...]

Skala MC,Riching KM,Gendron-Fitzpatrick A,Eickhoff J,Eliceiri KW,White JG,Ramanujam N. In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia., . Proceedings of the National Academy of Sciences of the United States of America Abstract [More ...]

Berchuck A. Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists., , (3552) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology No abstract available [More ...]

---

Click here for these and other high-impact publications in this research program.